Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Optimaliseren follow-upstrategie na fertiliteitsparende chirurgie voor cervixcarcinoom
jan 2024 | Gynaecologische oncologie